4月10日,先声药业(02096)发布公告,宣布其自主研发的抗肿瘤候选药物FGFR2b抗体偶联药物(SIM0686)已获得中国国家药品监督管理局签发的药物临床试验批准通知书,计划开展晚期实体瘤的临床试验。该药物是一款靶向FGFR2b的ADC药物,旨在用于治疗胃癌和肺癌等晚期恶性肿瘤。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.